Gordon J. Freeman, PhD, of Dana-Farber Cancer Institute, will receive the 2024 AACR-Cancer Research Institute (CRI) Lloyd J. Old Award in Cancer Immunology from the American Association for Cancer Research (AACR). The award will be presented during the AACR Annual Meeting, to be held April 5-10, 2024, in San Diego, California. The AACR-CRI Lloyd J. Old Award in Cancer Immunology recognizes active scientists whose outstanding and innovative research has had a major impact on the cancer field and has the potential to stimulate new directions in cancer immunology.
Freeman is being recognized for his groundbreaking contributions to the discovery of the T-cell programmed death-1 receptor (PD-1) signaling pathway and the PD-1 ligands, PD-L1 and PD-L2; for spotlighting the involvement of this pathway in tumor evasion of immunosurveillance; and for demonstrating that blocking this pathway can provoke an antitumor immune response. His extraordinary work has led to the development of immunotherapies for cancer, autoimmune diseases, and transplant rejection.
